Medimaps: Drug Information Tool for Patients
- Patients, family members, and caregivers in Spain now have a new resource to navigate the complex journey of medication access: Medimaps.
- The path from prosperous clinical trials to a medication reaching patients is frequently enough lengthy and opaque.
- Medimaps aggregates information from official European and Spanish sources, eliminating the need for patients and organizations to spend time on self-reliant research, translations, and interpretations.
“`html
Medimaps: New Tool Empowers Spanish Patients to Track Medication Availability
What is Medimaps and Why does It Matter?
Patients, family members, and caregivers in Spain now have a new resource to navigate the complex journey of medication access: Medimaps. Developed by the European Academy of Patients on Therapeutic Innovation (EUPATI) in Spain, this tool was unveiled at The XII Day We are Patients conference, themed ‘medicines that improve lives: the innovation that comes’.Medimaps addresses a critical gap in information accessibility, allowing users to track the status of medications from clinical trial completion through European authorization, national coding, and public financing within the Spanish National Health System (SNS).
The Journey of a Medication: From Trial to Patient
The path from prosperous clinical trials to a medication reaching patients is frequently enough lengthy and opaque. Before a new drug becomes available, it must undergo several administrative steps, including European authorization and price/financing negotiations with the Ministry of Health. medimaps illuminates this process, providing clarity on where a medication stands at each stage. Many promising treatments are currently in this pipeline, and Medimaps aims to provide patients with the information they need to understand their therapeutic options.
The platform specifically tracks:
- European Authorization: Whether a medication has been approved for use in Europe.
- National Code Request: If a request for a national code (necessary for use within the SNS) has been submitted.
- Public Financing: Whether the medication is publicly financed by the SNS.
- Financing Status Changes: Updates on any changes to the financing status of a medication.
- Authorization Indications: Potential changes to the approved uses (indications) of a medication.
How Medimaps Works: data sources and User Benefits
Medimaps aggregates information from official European and Spanish sources, eliminating the need for patients and organizations to spend time on self-reliant research, translations, and interpretations. As Roberto Saldaña, Director of Innovation and Citizen Participation at EUPATI, explained, “In Medimaps we collect information from European and Spanish official sources, saving patient organizations and citizens in general in consultations, translations and conclusions.”
isabel Pneros, Director of the pharmaceutical Provision and Access Department of Farmaindustria, highlighted the importance of this transparency, emphasizing the collaborative effort needed to ensure patients have access to innovative treatments.
Understanding the Financing landscape: A Simplified View
| Financing Status | Meaning for Patients |
|---|---|
| Not Financed | Medication is approved in Europe but not yet covered by the SNS. Patients may need to pay out-of-pocket. |
| Pending Financing | The Ministry of Health is evaluating whether to finance the medication. |
| Financed | Medication is covered by the SNS and accessible to eligible patients. |